Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

190/433 Matches for
“liver injury”

“liver injury” Clear all
  1. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 100

    …better biomarkers of drug-induced-liver-injury (DILI). ### Aims We aimed to…

    ActiTest FibroTest Other

  2. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.

    Mahamid M et al. · Clin Pharmacol · 2011 Match 100

    …Other possible etiologies for liver injury were excluded. Discontinuation of anakinra led…

    FibroTest Other

  3. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 100

    ActiTest AshTest FibroTest NashTest +6

  4. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 100

    liver injury. ### Conclusion A number of non-invasive markers of liver damage…

    NashTest SteatoTest Metabolic

  5. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 99

    …transferrin (CDT%), is confounded by liver disease severity. The aim was to…

    FibroTest SteatoTest Alcohol

  6. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 99

    ### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…

    FibroTest NashTest SteatoTest Metabolic

  7. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Match 99

    …Progressive liver injury is a concern in HIV-infected children exposed to…

    FibroTest HIV

  8. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 99

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    ActiTest FibroTest NashTest SteatoTest +1

  9. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 98

    …severity of nocturnal hypoxia and liver injury was established only in morbid…

    FibroTest NashTest SteatoTest Metabolic

  10. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.

    Knop V et al. · Nutrition · 2019 Match 98

    …risk for intestinal failure-associated liver disease (IFALD). The aim of the…

    FibroTest SteatoTest Other

  11. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 98

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury

    ActiTest FibroTest HCV

  12. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 98

    ActiTest AshTest FibroTest NashTest +7

  13. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 97

    …Steatosis was demonstrated in all 5 patients who received liver biopsies during…

    FibroTest Other

  14. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.

    Dominguez S et al. · J Antimicrob Chemother · 2010 Match 97

    …infected patients with liver disease documented by liver biopsy, matched with HIV…

    FibroTest HCV HIV

  15. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

    Poynard T et al. · Comp Hepatol · 2004 Match 97

    …alternative to liver biopsy for the assessment of liver injury in patients…

    ActiTest FibroTest HCV

  16. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 97

    ### Background Liver biopsy is considered the gold standard for assessing histologic lesions…

    NashTest Metabolic

  17. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 96

    FibroTest Alcohol

  18. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 96

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  19. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 96

    …The rate of adoption of non-invasive diagnostic tests for liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  20. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 95

    …of non-invasive biomarkers in liver fibrosis. A scoring system has been…

    ActiTest FibroTest SteatoTest Alcohol +5

  21. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 95

    Liver biopsy, owing to its limitations and risks, is an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  22. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 95

    ActiTest FibroTest Alcohol HBV +3

  23. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.

    Halfon P et al. · Am J Gastroenterol · 2006 Match 95

    …a non-invasive alternative to liver biopsy in patients with chronic hepatitis…

    ActiTest FibroTest HCV

  24. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 94

    …Non-invasive diagnostics of liver injury may be useful in screening to…

    ActiTest FibroTest SteatoTest Metabolic

  25. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 94

    …of alcohol-related liver injury is histology, liver biopsy is not reasonable…

    FibroTest Alcohol

  26. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 94

    …As for the prediction of liver injury, the concordance between fasting and…

    ActiTest FibroTest Alcohol HBV +3

  27. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 94

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  28. Glycogenic hepatopathy.

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Match 93

    …GH may be diagnosed also after elevated liver enzymes in routine blood…

    FibroTest Metabolic

  29. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 93

    Liver biopsy, due to its limitations and risks, is an imperfect gold…

    ActiTest FibroTest SteatoTest Alcohol +5

  30. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Match 93

    …Among the 2,169 patients who underwent liver biopsy, bridging fibrosis (F2…

    FibroTest HCV

  31. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Match 93

    ### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…

    FibroTest HCV

  32. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2013 Match 92

    FibroTest Metabolic

  33. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Match 92

    …vs placebo was assessed on liver injury according to baseline stage and…

    ActiTest FibroTest HBV

  34. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.

    Poynard T et al. · Antivir Ther · 2010 Match 92

    ### Background Liver biopsy and virological end points are standard references for assessing…

    ActiTest FibroTest HBV HCV +1

  35. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013 Match 92

    …Four cases of primary liver cancer occurred in SVR [4.6% (0…

    FibroTest HCV

  36. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 91

    …Fatty liver was diagnosed with abdominal ultrasound and liver steatosis was quantified…

    FibroTest SteatoTest Metabolic

  37. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 91

    …followed for a risk of liver fibrosis risk in the USA (212…

    FibroTest COVID

  38. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection.

    Hermeziu B et al. · Gastroenterol Clin Biol · 2010 Match 91

    …as a noninvasive alternative to liver biopsy (LB), but there are few…

    ActiTest FibroTest HCV

  39. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 90

    FibroTest Metabolic

  40. Liver biopsy: the best standard...when everything else fails.

    Poynard T et al. · J Hepatol · 2009 Match 90

    FibroTest Alcohol HBV HCV +1

  41. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 90

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  42. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 90

    …enrolled 103 patients for whom liver biopsy, hepatic elastography results, and laboratory…

    ActiTest FibroTest AIH

  43. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 89

    …Ten year survival (95% CI) without liver-related death in patients with…

    FibroTest Alcohol HBV HCV +1

  44. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 89

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    FibroTest Metabolic

  45. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 89

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  46. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 89

    …antifibrotic properties and may reduce liver injury in NASH. To date, no…

    FibroTest Metabolic

  47. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 88

    …major determinant of progression of liver injury. This study evaluated FibroMax™ for…

    HCV

  48. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 88

    liver function tests will miss most patients with significant liver injury. New…

    FibroTest Other

  49. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 88

    …of liver disease severity. ### Objective To compare the awareness of liver disease…

    ActiTest FibroTest Alcohol HBV +3

  50. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 88

    …SVR benefits are well-recognized with reductions in rates of liver complications…

    FibroTest HCV

  51. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 87

    …The best marker of liver fibrosis in alcoholic patients seems to be…

    FibroTest Alcohol

  52. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.

    Friedrich-Rust M et al. · J Thorac Cardiovasc Surg · 2008 Match 87

    …Transient elastography has been evaluated for noninvasive staging of liver fibrosis in…

    ActiTest FibroTest Other

  53. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 87

    …Although, liver biopsy is still considered as gold standard to identify liver

    FibroTest HCV

  54. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Match 87

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  55. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 86

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  56. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Match 86

    ### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…

    ActiTest HCV

  57. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 86

    ### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  58. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 85

    ### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver

    FibroTest SteatoTest Metabolic

  59. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 85

    …2-diabetes (T2D), obesity, and liver fibrosis (resmetirom) announce the widespread use…

    FibroTest-T2D Metabolic

  60. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 85

    …CHB and its consequences on liver injury compared with CHC and NAFLD…

    FibroTest SteatoTest HBV HCV +1

  61. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 85

    …in the prediction of primary liver cancer in patients without cirrhosis. ### Aim…

    LCR1 LCR2 Alcohol HBV +4

  62. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

    Grigorescu M et al. · J Gastrointestin Liver Dis · 2007 Match 84

    …in order to avoid the liver biopsy currently used for selection of…

    FibroTest HCV

  63. Noninvasive assessment of portal hypertension in patients with cirrhosis.

    Thabut D et al. · Hepatology · 2011 Match 84

    Severe portal hypertension is responsible for complications and death. Although measurement of…

    FibroTest Alcohol HBV HCV +3

  64. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.

    Carlson JJ et al. · J Gastroenterol Hepatol · 2009 Match 84

    …In comparison with liver biopsy alone, there was a cost savings of…

    FibroTest

  65. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.

    Montaudié H et al. · J Eur Acad Dermatol Venereol · 2011 Match 84

    …ideal method for monitoring the liver toxicity of MTX in the management…

    FibroTest Other

  66. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 83

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  67. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 83

    ActiTest FibroTest HCV

  68. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 83

    Liver disease in UCDs may be associated with hepatic inflammation, hepatic fibrosis…

    ActiTest FibroTest Other

  69. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 83

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  70. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 82

    …The optimal cut-off values of liver stiffness (LS) for predicting METAVIR…

    FibroTest Alcohol

  71. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 82

    liver pathologies, and provide accurate staging of the degree of liver injury

    FibroTest Alcohol

  72. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 82

    FibroTest SteatoTest Metabolic

  73. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 82

    ### Aim The objective of this study was to evaluate liver fibrosis using…

    FibroTest

  74. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 81

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  75. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 81

    ### Background Biopsy is the usual gold standard for liver steatosis assessment. The…

    SteatoTest Alcohol HBV HCV +1

  76. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 81

    …evaluated for the assessment of liver fibrosis predominantly in patients with viral…

    FibroTest SteatoTest Other

  77. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 80

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  78. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 80

    Chronic hepatitis B virus (HBV) infection is a major cause of liver

    FibroTest HBV

  79. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 80

    FibroTest HBV

  80. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 80

    …For the prediction of survival without liver-related death, the areas under…

    FibroTest Alcohol HBV HCV +3

  81. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Match 79

    …these findings in women and in people with other chronic liver diseases.

    FibroTest HCV

  82. FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.

    Munteanu M et al. · Liver Int · 2014 Match 79

    FibroTest HBV

  83. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 79

    FibroTest Metabolic

  84. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Match 79

    ### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…

    FibroTest HCV HIV

  85. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.

    Chládek J et al. · J Eur Acad Dermatol Venereol · 2013 Match 78

    …However, its use is hampered by the risk of liver fibrosis. ### Aim…

    FibroTest Other

  86. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

    Poynard T et al. · Aliment Pharmacol Ther · 2007 Match 78

    …the entire liver and one taking into account the prevalence of each…

    FibroTest HCV

  87. Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

    Fontanges T et al. · Gastroenterol Clin Biol · 2008 Match 78

    …practice and in comparison with liver biopsy the limitations of two blood…

    ActiTest FibroTest HCV

  88. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Match 78

    …The main endpoint was the absence of liver-related complications, transplantation or…

    ActiTest FibroTest HCV

  89. Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.

    Brühl J et al. · Eur J Gastroenterol Hepatol · 2011 Match 77

    …Results of noninvasive liver fibrosis markers were as follows: fibrotest,-1.65…

    FibroTest Other

  90. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 77

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  91. Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?

    Ofei SY et al. · Int J Cardiol · 2015 Match 77

    FibroTest Other

  92. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Match 77

    ### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…

    FibroTest COVID

  93. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2012 Match 76

    ### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…

    Elasto-FibroTest FibroTest HCV

  94. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 76

    ### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…

    FibroTest Alcohol HBV HCV +1

  95. Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.

    Munteanu M et al. · Am J Gastroenterol · 2014 Match 76

    FibroTest HBV

  96. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.

    Stibbe KJ et al. · Scand J Gastroenterol · 2011 Match 75

    ### Objective Chronic viral hepatitis B and C cause liver fibrosis, leading to…

    FibroTest HBV HCV

  97. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Match 75

    …and TE were predictive of liver complications (n=37; AUROC=0.83…

    ActiTest FibroTest HBV

  98. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 75

    Liver fibrosis, as the last stage of numerous chronic liver diseases, is…

    ActiTest FibroTest Alcohol HBV +2

  99. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Match 75

    …patients with chronic liver disease or normal liver tissue that surrounded tumors…

    FibroTest Alcohol HBV HCV +3

  100. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Match 74

    …FibroSure; LabCorp, Burlington, USA) and liver stiffness measurement (LSM) by Fibroscan (Echosens…

    FibroTest HBV

  101. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Match 74

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  102. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 74

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  103. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 74

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  104. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 73

    ### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…

    FibroTest Alcohol HBV HCV +1

  105. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 73

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  106. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Match 73

    The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea…

    FibroTest NashTest SteatoTest Metabolic

  107. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

    Poynard T et al. · Hepatology · 2003 Match 73

    …Three hundred fifty-two patients who had had 2 interpretable liver biopsies…

    ActiTest FibroTest HCV

  108. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 72

    …the final result of injury to the liver. Accurate assessment of the…

    FibroTest SteatoTest HBV HCV +1

  109. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 72

    …UK Biobank with apparently healthy liver participants (middle-aged, n=138,125…

    FibroTest

  110. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 72

    …for the diagnostic of metabolic liver disease in patients with type-2…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  111. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 72

    ### Introduction Identifying liver fibrosis is important to evaluate the severity of liver

    FibroTest

  112. American Association for the Study of the Liver

    Match 71

    FibroTest HCV

  113. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 71

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  114. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 71

    ActiTest FibroTest HCV

  115. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.

    Haseltine EL et al. · J Viral Hepat · 2015 Match 70

    Patients infected with hepatitis C virus (HCV) have differing levels of liver

    FibroTest HCV

  116. The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.

    Sökücü S et al. · Scand J Infect Dis · 2010 Match 70

    …decreases the need for a liver biopsy. Twenty-five children with naïve…

    ActiTest FibroTest HBV

  117. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Match 70

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver

    FibroTest HCV

  118. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 70

    Liver biopsy, because of its limitations and risks, might be considered an…

    ActiTest FibroTest HCV

  119. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 69

    …Given that early identification of non-alcoholic fatty liver disease (NAFLD) is…

    NashTest SteatoTest Metabolic

  120. Hepatitis B: are non-invasive markers of liver fibrosis reliable?

    Castera L · Liver Int · 2014 Match 69

    …However, as none are liver specific their results can be influenced by…

    FibroTest HBV HCV

  121. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 69

    The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…

    ActiTest FibroTest NashTest SteatoTest +1

  122. Effective use of FibroTest to generate decision trees in hepatitis C.

    Lau-Corona D et al. · World J Gastroenterol · 2009 Match 69

    …chronic hepatitis C without a liver biopsy. The FibroTest attributes of age…

    FibroTest HCV

  123. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 68

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  124. Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores.

    Férard G et al. · Clin Chem Lab Med · 2006 Match 68

    liver fibrosis or necro-inflammatory lesions as an alternative to liver biopsy…

    ActiTest FibroTest HBV HCV

  125. Liver fibrosis markers in alcoholic liver disease.

    Chrostek L et al. · World J Gastroenterol · 2014 Match 68

    Alcohol is one of the main factors of liver damage. The evaluation…

    FibroTest Alcohol

  126. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Match 68

    Fontan-associated liver disease (FALD) is a serious complication related to the…

    FibroTest Other

  127. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Match 67

    Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…

    FibroTest HCV

  128. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.

    Canbakan M et al. · Nephron Clin Pract · 2011 Match 67

    ### Background Liver biopsy is an imperfect gold standard for assessing the disease…

    FibroTest HCV

  129. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 67

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  130. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Match 67

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver

    FibroTest Other

  131. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.

    Wu FM et al. · J Heart Lung Transplant · 2017 Match 66

    …Further studies are needed to guide strategies for surveillance of liver disease…

    FibroTest

  132. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 66

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  133. Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics.

    Schleiger A et al. · Pediatr Cardiol · 2020 Match 66

    …Severe liver cirrhosis was detectable in 20 patients (17.1%). Median liver

    FibroTest Other

  134. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.

    Dai CY et al. · J Hepatol · 2010 Match 65

    ### Background & Aims Hepatitis C virus (HCV) infection has been shown to be…

    FibroTest HBV HCV

  135. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Match 65

    …42.6 +/- 11.3) with CHB undergoing diagnostic liver biopsy were included…

    FibroTest HBV

  136. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 65

    Liver biopsy is the reference standard for assessment of liver fibrosis. However…

    FibroTest HBV

  137. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Match 65

    …The use of FT may decrease the need for liver biopsy examination.

    FibroTest Alcohol

  138. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003 Match 64

    ### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…

    ActiTest FibroTest HBV

  139. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 64

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  140. Altered serum N-glycomics in chronic hepatitis B patients.

    Gui HL et al. · Liver Int · 2010 Match 64

    …markers for the diagnosis of liver fibrosis in patients with chronic hepatitis…

    FibroTest HBV

  141. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

    Calin R et al. · J Clin Virol · 2013 Match 64

    …The dynamic of liver disease in co-infected patients is important to…

    FibroTest HBV HIV

  142. Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.

    Bosselut N et al. · Clin Chim Acta · 2013 Match 63

    ### Background Noninvasive methods for liver fibrosis evaluation in chronic liver diseases have…

    FibroTest HCV

  143. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.

    Corradi F et al. · Dig Liver Dis · 2009 Match 63

    ### Background Progression of recurrent hepatitis C is accelerated in liver transplant recipients…

    FibroTest HCV

  144. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.

    d'Arondel C et al. · J Viral Hepat · 2006 Match 63

    In therapy with standard interferon and ribavirin, five independent risk factors (RF…

    ActiTest FibroTest HCV

  145. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Match 63

    Liver-related and non-liver-related outcomes were documented. Overall 213 episodes…

    FibroTest HCV HIV

  146. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Match 62

    …confirmed by Fibromax testing (or liver biopsy/Fibroscan). Efficacy was assessed by…

    FibroTest HCV

  147. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 62

    …We reviewed the landmark studies in metabolic liver disease, sources of the…

    ActiTest FibroTest NashTest NashTest-2 +3

  148. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

    Friedrich-Rust M et al. · BMC Gastroenterol · 2010 Match 62

    …The Enhanced Liver Fibrosis (ELF) test consists of an algorithm of three…

    FibroTest HBV HCV Other

  149. Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.

    Yakoob R et al. · Ann Gastroenterol · 2015 Match 62

    …hepatitis C (CHC) patients with liver biopsy (LB). ### Methods In 107 patients…

    ActiTest FibroTest HCV

  150. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Match 61

    ### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…

    FibroTest Alcohol

  151. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Match 61

    ### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…

    FibroTest HCV

  152. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.

    Naveau S et al. · Eur J Gastroenterol Hepatol · 2014 Match 61

    …one of the first composite liver fibrosis markers. This study aims, prospectively…

    FibroTest Alcohol

  153. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 60

    …compared with FibroTest (FT) and liver stiffness measurement (LSM) by transient elastography…

    FibroTest Alcohol HBV HCV +3

  154. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 60

    …AshTest is an appropriate non-invasive alternative to transjugular liver biopsy.

    AshTest Alcohol

  155. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 60

    …Evaluation of liver fat was performed using four noninvasive methods: the SteatoTest…

    SteatoTest Metabolic

  156. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 60

    ActiTest FibroTest HBV

  157. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Match 59

    …Histologic staging of liver fibrosis served as the reference standard. ### Results Liver

    FibroTest Alcohol HBV HCV +2

  158. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.

    Sturm N et al. · Liver Int · 2013 Match 59

    ### Background Liver fibrosis, now assessed by liver biopsy or using non-invasive…

    FibroTest HBV HCV

  159. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Match 59

    …All patients had a liver biopsy. The Hepascore and FibroTest were calculated…

    FibroTest Other

  160. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013 Match 59

    ### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…

    FibroTest HCV

  161. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 58

    …The use of AshTest may reduce the need for liver biopsy, and…

    AshTest Alcohol

  162. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 58

    ActiTest FibroTest HBV

  163. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

    Poynard T et al. · J Hepatol · 2013 Match 58

    …Blinded liver biopsies obtained before retreatment and after maintenance therapy were evaluated…

    ActiTest FibroTest HBV

  164. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Match 58

    …competitor as a biomarker of liver fibrosis in comparison with the standard…

    ActiTest FibroTest SteatoTest Alcohol +3

  165. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.

    Zarski JP et al. · Liver Int · 2010 Match 57

    …Blood tests could be useful to assess liver fibrosis changes in clinical…

    ActiTest FibroTest HCV

  166. [Prognosis assessment of alcoholic liver disease: how and why?].

    Trabut JB et al. · Presse Med · 2014 Match 57

    Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…

    FibroTest Alcohol

  167. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Match 57

    …elastography (TE) and biomarkers for liver fibrosis assessment and follow-up of…

    FibroTest HBV

  168. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 57

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…

    NashTest-2 SteatoTest-2 Metabolic

  169. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 56

    …is the prediction of metabolic liver disease (MLD) by noninvasive tests (NITs…

    FibroTest NashTest SteatoTest Metabolic

  170. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 56

    ### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  171. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 56

    …infection or non-HCV-related liver diseases. ### Methods And Results The optimal…

    FibroTest Alcohol HBV HCV +2

  172. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 55

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  173. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 55

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  174. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.

    Dezanet LNC et al. · Liver Int · 2021 Match 55

    ### Background & Aims Data on liver fibrosis evolution and its involvement in liver

    FibroTest HBV HIV

  175. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 55

    …Since liver biopsy is invasive, expensive and prone to sampling error, several…

    FibroTest Metabolic

  176. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 54

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  177. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 54

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  178. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 54

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  179. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 54

    …and metabolic-dysfunction-associated steatotic liver disease (MASLD); however, the underlying mechanisms…

    FibroTest Metabolic

  180. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 53

    …the prediction of non-alcoholic liver disease by non-invasive blood tests…

    FibroTest NashTest-2 SteatoTest Metabolic

  181. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 53

    FibroTest Alcohol HBV HCV +3

  182. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 53

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  183. [Biomarkers for liver fibrosis: advances, advantages and disadvantages].

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 53

    Liver cirrhosis in Mexico is one of the most important causes of…

    FibroTest HCV

  184. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 52

    Liver biopsy samples, NIT results, and PROs (Short Form-36, Chronic Liver

    FibroTest Metabolic

  185. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 52

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  186. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Match 52

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  187. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 52

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  188. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 51

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  189. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 51

    FibroTest HCV

  190. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.